Mode of action of plectasin-derived peptides against gas gangrene-associated *Clostridium perfringens* type A

Xueling Zheng¹,², Xiumin Wang¹,², Da Teng¹,²*, Ruoyu Mao¹,², Ya Hao¹,², Na Yang¹,², Lifen Zong¹,², Jianhua Wang¹,²*

¹ Key Laboratory of Feed Biotechnology, Ministry of Agriculture, Beijing, China, ² Gene Engineering Laboratory, Feed Research Institute, Chinese Academy of Agricultural Sciences, Beijing, China

* wangjianhua@caas.cn (JW); tengda@caas.cn (DT)

Abstract

NZ2114 and MP1102 are novel plectasin-derived peptides with potent activity against Gram-positive bacteria. The antibacterial characteristics and mechanism of NZ2114 and MP1102 against gas gangrene-associated *Clostridium perfringens* were studied for the first time. The minimal inhibitory concentration and minimal bactericidal concentration of NZ2114 and MP1102 against resistant *C. perfringens* type A strain CVCC 46 were 0.91 μM. Based on the fractional inhibitory concentration index (FICI) result, an additive or synergic effect was observed between NZ2114 (FICI = 0.5~0.75) or MP1102 (FICI = 0.375~1.0) and antibiotics. The flow cytometry, scanning and transmission electron microscopy analysis showed that both NZ2114 and MP1102 induced obviously membrane damage, such as the leakage of cellular materials, partial disappearance of the cell membrane and membrane peeling, as well as retracting cytoplasm and ghost cell. The gel retardation and circular dichroism (CD) detection showed that NZ2114 and MP1102 could bind to *C. perfringens* genomic DNA and change the DNA conformation. Moreover, NZ2114 also interfered with the double helix and unwind the genomic DNA. The cell cycle analysis showed that *C. perfringens* CVCC 46 cells exposed to NZ2114 and MP1102 were arrested at the phase I. These data indicated that both NZ2114 and MP1102 have potential as new antimicrobial agents for gas gangrene infection resulting from resistant *C. perfringens*.

Introduction

An anaerobic Gram-positive bacterium-*Clostridium perfringens* is broadly distributed in our environment, coexisting with foods, sewage water, soils, feces and the normal intestinal microbiota of human and animals [1]. The *C. perfringens* strains are subdivided into five toxigenotypes (A–E) on the basis of the production of toxins, including α, β, ε and τ [1,2], which leading to a wide range of diseases in humans or livestock, ranging from type A gas gangrene to enteritis syndromes [3]. Type C infections are common in newborn animals due to rapid colonization in intestine, which cause a well-known disease syndrome, but type A infections are now recognized with increasing frequency in neonatal and weaned animals, which result in gas
accumulation; approaches to control is both different and more complex than those of type C infections [4]. Herein, gas gangrene is an acute rapidly progressive disease that affects muscle tissue, fascia and skin infection, which characterized by marked tissue destruction, gas production, sepsis, and massive death of tissue [5]. Gas gangrene infection consists of spontaneous and traumatic gangrene and approximately 80% traumatic gangrene is caused by \textit{C. perfringens} [5].

Antibiotics play a crucial role in clinical treatment of diseases caused by \textit{C. perfringens}. However, misuse or overuse of antibiotics has caused emergence and spread of many multi-drug-resistant (MDR) \textit{C. perfringens} [6–8]. Many commonly used antibiotics, such as tetracycline, bacitracin, and lincomycin, were found to have a mild or weak antibacterial activity toward pathogenic \textit{C. perfringens} [6,9]. Moreover, horizontal diffusion of resistant genes increased by genetic background flow factor of \textit{C. perfringens} leads to a rise in MDR strains, which made the therapy of \textit{C. perfringens} infections more complicated [10]. In addition, the emergence of MDR bacterium and the ban of antibiotics as growth promoters in the Europe and other countries have resulted in an urgent need to discover novel compounds to combat \textit{C. perfringens} infection diseases in the postantibiotic era [11,12].

Plectasin, the first known fungal defensin isolated from \textit{Pseudoplectania nigrella}, can inhibit cell wall synthesis by interacting with the peptidoglycan precursor-Lipid II [13]. Unlike other defensins, plectasin and its analogues-NZ2114, MP1102, and MP1106 have narrow-spectrum antimicrobial activity against Gram-positive bacteria, particularly \textit{Staphylococcus aureus}, \textit{Streptococcus suis}, \textit{Streptococcus pneumoniae}, and \textit{Staphylococcus epidermidis} [14–17], and they are non-hemolytic or non-cytotoxic toward human erythrocytes, epidermal keratinocytes, A549 cells, murine L929 fibroblasts, and porcine intestinal epithelial cell line ZYMSIEC02 [14–21]. In addition, NZ2114, MP1102 and MP1106 showed improved potency and better pharmacokinetic properties in different aspects than its parental peptide-plectasin, including antibacterial activity especially against penicillin- and vancomycin-resistant \textit{S. aureus}, \textit{S. pneumoniae} and \textit{S. suis} strains, the postantibiotic effect, synergistic effect with antibiotics, and stability [15–17]. These findings suggest that plectasin and its derivatives may be attractive candidates for human and animal therapeutic agents. Additionally, our previous study has revealed the mode of action of MP1102 against \textit{C. perfringens} type C, which including cell membrane damage, interaction with DNA, and cell cycle arrest in I phase. However, antibacterial characteristics and mode of action of NZ2114 and MP1102 against gas gangrene-related \textit{C. perfringens} type A have not yet been elucidated.

In our pre-experiment, the antibiotic sensitivity testing result showed that \textit{C. perfringens} type A CVCC 46 can resist multiple antibiotics such as lincomycin, bacitracin, streptomycin, cefotaxime, vancomycin, neomycin, azithromycin, kanamycin, gentamicin, and tetracycline (data not shown). In this study, the antibacterial activity of both NZ2114 and MP1102 toward pathogenic \textit{C. perfringens} type A CVCC 46 and their antibacterial action, including disruption of the cell membrane and genomic DNA, were elucidated for the first time, as well as effect on the cell morphology.

### Materials and methods

#### Materials

Both NZ2114 and MP1102 were prepared by using the \textit{Pichia pastoris} expression system according to our previous protocols [16,17], with the purities of 94.8% and 96.4%. The resistant \textit{C. perfringens} CVCC 46, CVCC 51, and CVCC 1337 strains, which isolated from piglet and rabbit infected gas gangrene, were obtained from the China Veterinary Culture Collection (CVCC). The MDR \textit{C. perfringens} strains of JT1, JZ10 and JC2, which isolated from broilers, was graciously provided by Professor Yanfen Jiang, College of Veterinary Medicine, Northwest A & F University.
The bacterial genome DNA extraction kit were supplied from TIANGEN Biotech (Beijing) Co., Ltd. Antibiotics including virginiamycin, aureomycin, bacitracin zinc, lincomycin and vancomycin were obtained from the China Institute of Veterinary Drug Control and Dalian Meilun Biotech and Sangon Biotech (Shanghai) Co., Ltd., respectively. The dye-propidium iodide (PI) was gotten from Sigma-Aldrich (China). All other reagents used meet the need of analytical level.

**Determination of antibacterial activity**

The minimum inhibitory and minimal bactericidal concentrations (MICs, MBCs) of NZ2114 or MP1102 toward *C. perfringens* strains (CVCC 46, JT1, JZ10, and JC2) were measured by a broth microdilution technique as reported previously [22,23]. Briefly, bacterial cells were anaerobically cultured in nutrient meat broth medium (Beijing Aoboxing Bio-Tech Co. Ltd.) to mid-log phase at 37˚C and diluted to 1×10^5 CFU/mL. Serial twofold dilutions of peptides (10 μL/well) were added into the wells of 96-well microplates, followed by addition of cells suspension (90 μL/well). The plates were incubated anaerobically at 37˚C for 12~18 h and the MICs and MBCs were measured according to the pervious described method [24]. All tests were carried out in triplicate.

**Growth kinetics measurement**

The time-kill assay was performed to evaluate the in vitro pharmacodynamics of both NZ2114 and MP1102 against *C. perfringens* CVCC 46 according to a previous method [25]. Briefly, bacterial cells were cultured in anaerobic meat broth medium overnight and diluted to 1×10^5 CFU/mL with the same medium. The bacterial cells (5 mL) were transferred into a flask (50 mL size) and followed by the addition of 2×MIC antibacterial drugs. After incubation at 37˚C, 100-μL samples were taken from each flask per hour, serially diluted in 0.9% NaCl, and plated to count colonies [26]. The 0.9% NaCl solution was used as a blank control, and conventional antibiotics were served as the positive one. They were repeated three times.

**Synergism assays between NZ2114 or MP1102 and antibiotics**

Synergism interaction between NZ2114/MP1102 and antibiotics were measured by using a chequerboard microtiter method [15]. A twofold dilution series of NZ2114, MP1102 and specific antibiotics (from 1/16 to 8×MIC) were added into 96-well microplates in accordance with MIC assay described above. The tests were conducted in triplicate. As described in detail the previous report, the fractional inhibitory concentration index (FICI) refers to the sum of the MIC of each drug when used in combination divided by the drug alone [27]. The data were analyzed by the following equation: FICI = (MIC\textsubscript{drug A in combination}/MIC\textsubscript{drug A alone}) + (MIC\textsubscript{drug B in combination}/MIC\textsubscript{drug B alone}) [23]. The interaction results were interpreted based on the FICI, as shown in the following: synergy (FICI ≤ 0.5), additivity (0.5 < FICI ≤ 1), indifference (1 < FICI ≤ 4), and antagonism (FICI > 4) as described in a previous study [28].

**Interaction of NZ2114 or MP1102 with the *C. perfringens* membrane**

Membrane permeabilization by flow cytometric analysis. After triple washing with 10 mM PBS (pH 7.4), the mid-logarithmic *C. perfringens* cells were diluted to 1×10^8 CFU/mL and followed by incubation with 1×MIC NZ2114 or MP1102 at 37˚C for different times of 5, 30, or 120 min, respectively. Following washing with buffer again, the bacterial cells were mixed with PI (50 μg/mL) at room temperature for 20 min and detected by a FACS Calibur Flow Cytometer (BD, USA) using the CellQuest Pro software (BD, USA) as described previously [29].
**Electron microscopy observation.** Scanning electron microscopy (SEM) is usually used to analyze cell surfaces at high resolution and observe cells morphology [30]. 4×MIC NZ2114 or MP1102 was added into the mid-logarithmic *C. perfringens* CVCC 46 (1×10⁸ CFU/mL) cells and incubated for 2 h at 37˚C. After centrifugation (1500×g, 5 min), the cells were washed for three times with PBS (0.1 M, pH 7.4) and then fixed in 2.5% glutaraldehyde overnight at 4˚C. After washing twice again, the cells were treated using an ethanol series of 50, 70, 85, 95, and 100% (15 min/time), dried by CO₂, sputtered with gold-palladium, and observed under a QUANTA200 SEM (FEI, Philips, Netherlands) [31].

Similarly, the bacterial cells were mixed with 4×MIC NZ2114 or MP1102, washed, and fixed in 2.5% glutaraldehyde at 4˚C overnight according to the above same method. After post-fixation in 1% buffered osmium tetroxide for 2 h, the samples were washed three times with PBS (0.1 M, pH 7.4), treated by the above ethanol series (50–70–85–95–100%), and followed by immerse in acetone and resin solutions. After embedding in Spur resin, the samples were then sectioned, put on Formvar carrier grids and followed by staining with 2% uranyl acetate and lead citrate. The microscopy was performed with a JEM-1400 (JEDL, Japan) [32].

**Interaction of NZ2114 or MP1102 with the bacterial genomic DNA**

**Gel retardation assay.** The genomic DNA were extracted from *C. perfringens* CVCC 46 with a bacterial DNA kit (TIANGEN, Beijing). The gel retardation experiment was conducted by mixing bacterial DNA with different concentrations of NZ2114 or MP1102 in 20 μL DNA binding buffer (10 mM Tris-HCl (pH 8.0), 5% glycerol, 20 mM KCl, 1 mM dithiothreitol, 1 mM EDTA, and 50 μg/mL BSA) as described previously [25]. The peptide/DNA ratios were 0, 0.5, 1, 2.5, 5.0, and 10.0 (w/w), respectively. The peptide/DNA solutions were mixed for 10 min at 37˚C and the migration of DNA was analyzed in 0.7% agarose gel by using a Geliance 200 imaging system (PerkinElmer, USA) [31].

**Circular dichroism (CD) spectroscopy.** The CD spectra of genomic DNA extracted from *C. perfringens* were measured to examine whether NZ2114 or MP1102 binding cause secondary structure changes in DNA as a previously described method [32]. Both peptides and genomic DNA were mixed at mass ratios of 0, 1.0, 2.5, and 10.0 respectively, incubated for 10 min at room temperature, loaded into a cuvette with 1.0-mm path length and followed by running at 25˚C on a CD spectrometer (Pistart π-180, Applied Photophysics, USA). Data are the average of 10 scans with an integration time of 20 s.

**Cell cycle analysis.** The bacterial DNA contents were analyzed by the PI-staining flow cytometry, and the assays were essentially carried out as previous method [33] with some modifications. In brief, 1×MIC peptide solution was added into the mid-log phase *C. perfringens* CVCC 46 cells (1×10⁸ CFU/mL) and incubated at 37˚C for 0.5 h or 2 h, respectively. After centrifugation for 5 min (1500×g) and washing twice with PBS, the cells were fixed in 75% cool-ethanol (1.8 mL) overnight at 4˚C, centrifuged and washed again, and followed by resuspension in 400 μL of PBS (containing 250 μg RNAse A). After incubation for 15 min at room temperature, the cells were stained with 50 μL 0.5 mg/mL PI for 15 min in the dark. Finally, the DNA content and cell cycle phase distribution were determined by a FACS Calibur Flow Cytometer with the ModFit LT software (version 4.1, BD, USA).

**Results**

**Antibacterial activity of NZ2114 and MP1102**

To evaluate the antimicrobial activity of NZ2114 and MP1102, the MIC and MBC determination were performed against four MDR *C. perfringens* strains. The MIC values of NZ2114, MP1102, plectasin, and antibiotics against *C. perfringens* CVCC 46, CVCC 51 and CVCC 1137
were 0.91, 0.91, 1.81, and 0.24-8.68 μM, respectively (Table 1), indicating that both peptides have higher antibacterial activity than plectasin and traditional antibiotics in the exception of bacitracin zinc (0.67 μM), virginiamycin (0.24-0.48 μM) or vancomycin (0.69 μM). Additionally, the MBC values of antibiotics and AMPs were identical to or higher than their MIC values. The MIC values of plectasin, NZ2114 and MP1102 against \( \text{C. perfringens} \) JT1 were 0.23 or 0.46 μM, equal to or lower than antibiotics (0.46-16.7 μM). Plectasin, NZ2114 and MP1102 displayed the lowest antibacterial activity of against \( \text{C. perfringens} \) JZ10 and JC2 with high MIC values (Table 1).

### Growth kinetics measurement

The time-kill curve was determined to evaluate the pharmacodynamics of NZ2114 and MP1102 toward MDR \( \text{C. perfringens} \) strain CVCC 46. As shown in Fig 1, the bacterial counts (Log10 CFU/mL) steadily increased to 7.8 for \( \text{C. perfringens} \) strain in the absence of antibacterial drugs at 6 h, afterwards, which kept nearly constant. After treatment with NZ2114 and MP1102, the bacterial counts have an amazing similarity, which slowly decreased within 0.5 h but sharply decreased half an hour later. Treatments with lincomycin, virginiamycin, and aureomycin led to a 99.9% reduction of bacterial counts within 2~4 h. However, regrowth of \( \text{C. perfringens} \) strain CVCC 46 was observed after being treated with aureomycin for 8 h. Additionally, a slightly decrease was be seen in vancomycin and bacitracin zinc treatment groups, which could lead to a 99.9% reduction of bacterial counts until 8 h. Overall, a reduction of bacterial counts of treatment of NZ2114 and MP1102 were more sharply than those of conventional antibiotics treatment at 2×MIC and no bacterial regrowth, compared with treatment with aureomycin, occurred within 10 h.

### Synergism between NZ2114 or MP1102 and antibiotics

As shown in Table 2, all the FICI results showed a synergic or additive effect between NZ2114 and virginiamycin, aureomycin, bacitracin zinc, lincomycin, and vancomycin against MDR \( \text{C. perfringens} \) CVCC 46 (FICI = 0.5~0.75). Similarly, an additive or synergic effect was observed between MP1102 and the tested antibiotics against \( \text{C. perfringens} \) CVCC 46 (FICI = 0.375~1.0). There were no indifference and antagonism.

### Table 1. In vitro antibacterial activities of AMPs and antibiotics against MDR \( \text{C. perfringens} \) strains.

| Antibacterial agents | CVCC 46 | CVCC 51 | CVCC 1137 | JT1 | JZ10 | JC2 |
|----------------------|---------|---------|-----------|-----|------|-----|
| **MIC (μM)**         |         |         |           |     |      |     |
| Plectasin            | 1.81    | 1.81    | ND        | 0.23| >14.5| >14.5|
| NZ2114               | 0.91    | 0.91    | 0.91      | 1.81| 0.46 | >14.5|
| MP1102               | 0.91    | 0.91    | 0.91      | 1.82| 0.46 | >14.5|
| Lincomycin           | 8.68    | 8.68    | 4.3       | 2.17| 2.2  | >277.6|
| Virginiamycin        | 0.96    | 0.96    | 0.24      | 0.48| 0.46 | 121.8|
| Bacitracin zinc       | 0.67    | 1.34    | 1.35      | 1.35| 0.67 | >86.1|
| Vancomycin           | 0.69    | 0.69    | 0.69      | 0.69| 0.69 | 22.1 |
| Aureomycin           | 4.18    | 8.36    | 1.04      | 0.52| 16.7 | 16.7 |

ND indicates no detection.

The CVCC 46 strain is resistant to lincomycin, bacitracin and other antibiotics; the CVCC 51 and CVCC 1137 strains are resistant to bacitracin, streptomycin, kanamycin, gentamycin and other antibiotics; the JT1, JC2 and JZ10 strains are resistant to vancomycin, virginiamycin, clindamycin, tetracycline and other antibiotics.

https://doi.org/10.1371/journal.pone.0185215.t001
Effects of NZ2114 or MP1102 on the cell membrane of *Clostridium perfringens*.  

**Inner membrane integrity.** After treatment with NZ2114 or MP1102, the membrane damage of *C. perfringens* cells was assayed by staining with PI-dye and then analyzed with a flow cytometer. The PI-permeated percentages of cells treated with 1×MIC NZ2114 for 5, 30, or 120 min were 41.6%, 69.0%, or 97.9%, respectively (Fig 2B and 2C), and those treated with 1×MIC MP1102 were 36.5% (5 min), 73.1% (30 min), and 96.7% (120 min), respectively (Fig 2F and 2G), which were much higher than those of the untreated cells (1.41%) (Fig 2A and 2E). This result indicated that the inner membrane of *C. perfringens* cells can be disrupted by both NZ2114 and MP1102.

**SEM observations.** SEM was used to directly observe the effects of NZ2114 or MP1102 on the cell morphology and integrity of MDR *C. perfringens* CVCC 46. As shown in Fig 3, it was observed that the untreated control group had normal intact cell morphology; there was no cellular disruption or release of intracellular content. However, after treatment with NZ2114 (Fig 3C–3F) or MP1102 (Fig 3G–3J), the cells exhibited obviously membrane damage (approximately 50%), such as membrane hole, peeling, and lysis, the leakage of cellular materials, and retracting cytoplasm.

**TEM observations.** After treatment with NZ2114 and MP1102, the cell morphology and intracellular changes were further detected by using TEM. The untreated *C. perfringens* cells had intact shapes and no damage was observed in membrane structure. Homogeneous electron density was observed in the cytoplasm (Fig 4A and 4B). However, after treatment with NZ2114 or MP1102, the morphology of the cells appeared deformed and a heterogeneous
electron density was observed in the cytoplasm, and (Fig 4D and 4F). It was also observed that the cell disruption, partial disappearance of the cell membrane, and the leakage of cellular material was occurred, which was consistent with the above SEM observation. In addition, retracting cytoplasm and ghost cell were observed in the peptide-treated cells.

Interaction of NZ2114 or MP1102 with the \textit{C. perfringens} cellular DNA

**DNA gel retardation.** The electrophoretic gel mobility shift assay was used to evaluate the DNA-binding capability of peptide to bacterial genomic DNA. As shown in Fig 5A and 5B, NZ2114 and MP1102 interacted with MDR \textit{C. perfringens} CVCC 46 genomic DNA. Nearly all DNA moved into the gel at a peptide/DNA mass ratio of 0.5, but the complete retardation in DNA-peptide migration did not appear even at a mass ratio of 10.0. The interaction of NZ2114 and MP1102 with DNA was also verified by the next CD spectroscopy.

**CD spectroscopy.** The CD spectrum is usually used to monitor changes in DNA morphology when drugs interact with DNA [34]. The affinity of NZ2114 and MP1102 binding to DNA were further detected using a CD spectrometer. It appeared a positive peak at approximately 270 nm and a negative one at about 245 nm in the CD spectrum of \textit{C. perfringens} genomic DNA (Fig 5C and 5D). After treatment with NZ2114 or MP1102, the DNA ellipticity intensity decreased, indicating the negative correlation with the peptide content. This suggested that NZ2114 and MP1102 maybe bind to \textit{C. perfringens} genomic DNA which changing the DNA conformation. There is a significant difference between NZ2114 and MP1102. The slight redshift was observed in NZ2114, indicating that NZ2114 interfere with the double helix

### Table 2. \textit{In vitro} activities of NZ2114 and MP1102 in combination with antibiotics against \textit{C. perfringens} CVCC 46.

| Combination                  | Variety        | MIC\textsubscript{a} (\textmu M) | MIC\textsubscript{C} (\textmu M) | FIC | FICI |
|------------------------------|----------------|---------------------------------|---------------------------------|-----|------|
| Bacitracin zinc-NZ2114       | Bacitracin zinc| 0.67                            | 0.1675                          | 0.25| 0.5  |
| NZ2114                      |                | 0.91                            | 0.2275                          | 0.25|      |
| Virginiamycin-NZ2114        | Virginiamycin | 0.96                            | 0.48                            | 0.5 | 0.75 |
| NZ2114                      |                | 0.91                            | 0.2275                          | 0.25|      |
| Lincomycin-NZ2114           | Lincomycin     | 8.68                            | 4.34                            | 0.5 | 0.625|
| NZ2114                      |                | 0.91                            | 0.11375                         | 0.125|     |
| Aureomycin-NZ2114           | Aureomycin     | 8.36                            | 4.18                            | 0.5 | 0.625|
| NZ2114                      |                | 0.91                            | 0.11375                         | 0.125|     |
| Vancomycin-NZ2114           | Vancomycin     | 0.69                            | 0.345                           | 0.5 | 0.75 |
| NZ2114                      |                | 0.91                            | 0.455                           | 0.2 |      |
| Bacitracin zinc-MP1102       | Bacitracin zinc| 0.67                            | 0.335                           | 0.5 | 1.0 |
| MP1102                      |                | 1.82                            | 0.91                            | 0.5 |      |
| Virginiamycin-MP1102        | Virginiamycin | 0.96                            | 0.12                            | 0.125| 0.375|
| MP1102                      |                | 1.82                            | 0.455                           | 0.25|      |
| Lincomycin-MP1102           | Lincomycin     | 8.68                            | 4.34                            | 0.5 | 0.625|
| MP1102                      |                | 1.82                            | 0.2275                          | 0.125|     |
| Aureomycin-MP1102           | Aureomycin     | 8.36                            | 2.09                            | 0.25| 0.375|
| MP1102                      |                | 1.82                            | 0.2275                          | 0.125|     |
| Vancomycin-MP1102           | Vancomycin     | 0.69                            | 0.345                           | 0.5 | 1.0 |
| MP1102                      |                | 1.82                            | 0.91                            | 0.5 |      |

MIC\textsubscript{a} indicates the MIC of drug used alone; MIC\textsubscript{C} indicates the MIC of drug used in combination.

\textsuperscript{a}Synergic effect.

\textsuperscript{b}Additive effect.

[https://doi.org/10.1371/journal.pone.0185215.t002](https://doi.org/10.1371/journal.pone.0185215.t002)
and unwind the genomic DNA. These results further illustrated that NZ2114 and MP1102 could interact with *C. perfringens* DNA.

**Cell cycle analysis.** The cell cycle of prokaryotes has three phases: the initiation (I), replication (R) and division (D). Once the bacterial DNA is disrupted, cell cycle progression will be inhibited and cell division can’t move into the next phase, causing cell cycle to remain in either phase [32]. After treatment with 1×MIC NZ2114 or MP1102 for 0.5 h and 2 h, *C. perfringens* CVCC 46 cell were detected by flow cytometry to analyze their effect on cell division. As showed in Fig 6, the ratios of the normal cells in I, R, and D phases were 3.86%, 80.52% and 15.61%, respectively. The ratio of *C. perfringens* cells treated with NZ2114 in phase I increased significantly, which ranging from 9.08% to 17.32%, while it decreased in phase R and D. Exposure to MP1102, the ratio of cells increased significantly from 8.14% to 13.65% in phase I, but
decreased in phase R and D. These results indicated both MP1102 and NZ2114 induced the cell cycle of *C. perfringens* arrested at I phase and seriously disturbed initiation of the cell cycle.

**Discussion**

Pathogenic *C. perfringens* acts as an important role in causing intestinal and histotoxic infections in humans and animals [2]. Over a long period in the past, antibiotics have been performed a vital status in curing disease caused by *C. perfringens*. However, with the emergence of many antibiotics resistance in *C. perfringens*, scientists have paid more attentions to search...
Fig 4. Transmission electron micrographs of *C. perfringens* CVCC 46 cells treated with NZ2114 and MP1102. (A, B) The untreated *C. perfringens* CVCC 46 cells. (C-F) The *C. perfringens* CVCC 46 cells treated with 4×MIC NZ2114 (C, D) and MP1102 (E, F) for 2 h, respectively.

https://doi.org/10.1371/journal.pone.0185215.g004

Fig 5. *In vitro* binding of NZ2114 and MP1102 to bacterial genomic DNA. (A, B) Gel retardation analysis of the binding of NZ2114 (A) and MP1102 (B) to genomic DNA. M: DNA Marker λDNA/HindIII. Lanes 1–6: genomic DNA from *C. perfringens* CVCC 46. The mass ratios of peptide and genomic DNA were 10, 5, 2.5, 1, 0.5, and 0, respectively. (C, D) CD spectra of genomic DNA from *C. perfringens* in the presence of NZ2114 (C) and MP1102 (D). The mass ratios of peptide to DNA were 0, 1.0, 2.5, and 10.0, respectively.

https://doi.org/10.1371/journal.pone.0185215.g005
for the newly effective alternatives to antibiotic usage [6–8]. Antimicrobial peptides (AMPs) are distributed in all living organisms as part of the host innate immunity [35] and they have rapidly become the promising therapeutic agents due to their potency and modes of action, including targeting the cell wall [13], cell membrane [36], or cytoplasm [37,38], interaction with DNA, and induction of the apoptosis-like cell death [32]. It has been demonstrated that NZ2114 and MP1102 display significant activity against Gram-positive bacteria, but not Gram-negative bacteria. Similarly to plectasin, NZ2114 and MP1102 may directly bind to Lipid II precursor of Gram-positive bacterial cell wall, which don’t occur in Gram-negative bacteria due to the large size (approximately 4.4 kDa) of both peptides [15,16], inhibiting the passage across the outer membrane [39,40].

Both NZ2114 and MP1102 have improved antibacterial activity against *S. aureus*, especially MRSA and MSSA strains, compared to their parental peptide-plectasin [15,16]; the same result of antibacterial activity of the two peptides against MDR *C. perfringens* was obtained in this study (Table 1). The bactericidal tendency of NZ2114 and MP1102 showed they could lead to a 99.9% reduction of bacterial counts within 1 h (Fig 1). The characteristics of high bactericidal
efficiency, low toxicity and no resistance of NZ2114 and MP1102 make them very attractive for future work.

Clinical monotherapy against \textit{C. perfringens} is limited by the increasing severity of antibiotics' resistance [9,41]. The results of antibacterial activities of NZ2114 or MP1102 combined with traditional antibiotics against MDR \textit{C. perfringens} CVCC 46 showed a synergic or additive effect between NZ2114 (FICI = 0.5–0.75) or MP1102 (FICI = 0.375–1.0) and virginiamycin, aureomycin, bacitracin zinc, lincomycin, and vancomycin (Table 2), which may improve antibacterial activity and help to reduce the amount of conventional antibiotics use to inhibit or delay the occurrence of bacterial resistance to antibiotics.

Most AMPs can disturb the cell membrane, which leading to morphological change in the membrane structure [23,32,42]. To determine whether both NZ2114 and MP1102 have an effect on the cell membrane, a membrane permeability assay was firstly performed using FACS. The PI dye is commonly used as a viability intracellular marker that can enter into the impaired cells and insert into DNA. The result of PI influx into \textit{C. perfringens} cells suggested that NZ2114 and MP1102 induced cytoplasmic membrane damage (Fig 3). Additionally, after treatment with 1×MIC NZ2114 and MP1102 for 5–120 min, the PI-stained percentages of \textit{C. perfringens} type A CVCC 46 cells were 41.6–97.9% and 36.5–96.7%, which were markedly higher than those of MP1102 against \textit{C. perfringens} type C CVCC 61 cells (3.11–5.67%) in our previous study [23]. This result indicated that MP1102 maybe have a different mode of action against \textit{C. perfringens} type A and against type C.

To further investigate the interaction between the two peptides and cell membrane, we tested the effects of NZ2114 and MP1102 on \textit{C. perfringens} cells morphology by SEM and TEM. After treatment with NZ2114 and MP1102, obvious cell membrane damage of \textit{C. perfringens} cells was found in SEM and TEM observation, such as the partial disappearance of the cell membrane, leakage of cellular materials, and membrane peeling (Fig 3 and Fig 4), which was similar to \textit{C. perfringens} type C CVCC 61 cells treated with MP1102 [23]. However, the phenomenon of retracting cytoplasm was not observed in the SEM of \textit{C. perfringens} type C CVCC 61 cells treated with the MP1102. The morphology and intracellular alterations in cells were also observed, such as cell disruption, retracting cytoplasm, and ghost cell (Fig 4), which is consistent with those of \textit{C. perfringens} ATCC 12915 cells treated with synthetic \(\beta\)-defensin Gallinacin-6, but with the exception of irregular septum formation in dividing cells [43]. This may be due to different \textit{C. perfringens} strain or peptide. Combining with the assays and observations of FACS, SEM, and TEM of MP1102 or NZ2114-treated bacteria, the results suggested that bacterial membranes was an important target of NZ2114 and MP1102.

Three residues substitution of NZ2114 (N9Q, L13V, and R14K) resulted in an increase in the \(\alpha\)-helix content (16.7%–33.3%) and hydrophobicity (0.48–0.56) of MP1102, but their positive charge and isoelectric point had no difference [16]. It is generally considered that the higher \(\alpha\)-helix index and hydrophobic moment of AMPs help to increase the ability of transmembrane and the interaction with the membrane [44–46]. However, in this study, no difference was found in the results of FACS, SEM, and TEM between MP1102 and NZ2114–treated bacteria, the results suggested that bacterial membranes was an important target of NZ2114 and MP1102.

More and more evidence showed that cell membrane is not the only way to kill pathogenic microorganisms, which suggests other potential intracellular targets and different mechanisms of killing bacteria [25,32,35]. Previous studies have proved that AMPs can also bind intracellular macromolecules and inhibit their synthesis and biological functions after they traverse the cell membrane and enter into the cytoplasm [31,33]. In this study, gel retardation and CD experiments suggested that NZ2114 and MP1102 can interact with the genomic DNA of \textit{C. perfringens} CVCC 46 by changing the DNA conformation (Fig 5). In addition, NZ2114 also interfered with the double helix and undid the genomic DNA (Fig 5C).
The interaction of AMPs and DNA may lead to disturb gene expression, transcription, and protein expression, which effectively shuts down or blocks the synthesis of macromolecules such as protein and receptor synthesis, causing the disruption of the bacterial life substances that results in cells death [33]. The cell cycle analysis showed that NZ2114 or MP1102-treated *C. perfringens* CVCC 46 cells were arrested at the phase I (Fig 6), which is consistent with that of *C. perfringens* CVCC 61 cells exposed to MP1102 [23]. Taken together with the gel retardation and CD, all these data indicated that DNA may be another target of MP1102 and NZ2114 and the binding affinity of the two peptides to genomic DNA may contribute to their antibacterial activity toward *C. perfringens*.

These results conferred a novel evidence of the antimicrobial action of NZ2114 and MP1102 toward MDR *C. perfringens* type A CVCC 46, which will lay the theoretic foundation for the application of NZ2114 and MP1102 as novel effective alternatives to antibiotics against gas gangrene-related *C. perfringens*.

In conclusion, MP1102 and NZ2114 showed the good antibacterial activity and a synergic or additive effect combining with virginiamycin, aureomycin, bacitracin zinc, lincomycin, and vancomycin. The antibacterial efficacy of the two peptides is ascribed to the cell membrane damage. Both NZ2114 and MP1102 can penetrate impaired membrane barrier, interfere DNA synthesis by altering DNA conformation and lead to the cell cycle arrest. Generally, the mode of action is related to destruction of the bacterial cell membrane and interference with bacterial DNA. Therefore, both NZ2114 and MP1102 have the potency to be developed as new candidates of antibacterial agents in the fight against gas gangrene infection caused by *C. perfringens*.

**Acknowledgments**

This study was supported by the National Natural Science Foundation of China (No. 31572445, 31372346, No.31572444, No.31672456, and No.31601968), the Project of the National Support Program for Science and Technology in China (No. 2013BAD10B02), and the AMP Direction of National Innovation Program of Agricultural Science and Technology in CAAS (CAAS-ASTIP-2013-FRI-02, 2013–2017).

**Author Contributions**

**Conceptualization:** Da Teng, Jianhua Wang.

**Data curation:** Ruoyu Mao.

**Formal analysis:** Xueling Zheng.

**Funding acquisition:** Da Teng, Jianhua Wang.

**Investigation:** Xueling Zheng.

**Methodology:** Na Yang.

**Project administration:** Ya Hao.

**Resources:** Lifen Zong.

**Software:** Xueling Zheng.

**Supervision:** Da Teng.

**Validation:** Da Teng.

**Visualization:** Xueling Zheng.
References

1. Li J, Adams V, Bannam TL, Miyamoto K, Garcia Garcia JP, Uzal FA, et al. Toxin plasmids of *Clostridium perfringens*. Microbiol Mol Biol Rev. 2013; 77(2):208–233. https://doi.org/10.1128/MMBR.00062-12 PMID: 23699255

2. Ma M, Gurjar A, Theoret JR, Garcia JP, Beingsesser J, Freedman JC, et al. Synergistic effects of *Clostridium perfringens* enterotoxin and Beta toxin in rabbit small intestinal loops. Infect Immun. 2014; 82(7):2958–2970. https://doi.org/10.1128/IAI.01848-14 PMID: 24778117

3. Uzal FA, Saputo J, Sayeed S, Vidal JE, Fisher DJ, Poon R, et al. Development and application of new mouse models to study the pathogenesis of *Clostridium perfringens* type C Enterotoxemias. Infect Immun. 2009; 77(12):5291–5299. https://doi.org/10.1128/IAI.00062-09 PMID: 19805537

4. Songer JG, Glock RD. Enteric infection of swine with *Clostridium perfringens* types A and C. Swine Heal Prod. 1998; 6(5):223–225.

5. Bryant AE, Stevens DL. *Clostridial myonecrosis*: new insights in pathogenesis and management. Curr Infect Dis Rep. 2010; 12(5):383–391. https://doi.org/10.1007/s11908-010-0127-y PMID: 21308521

6. Park M, Rooney AP, Hecht DW, Li J, McClane BA, Freedman JC, et al. Phenotypic and genotypic characterization of tetracycline and minocycline resistance in *Clostridium perfringens*. Arch Microbiol. 2010; 192(10):803–810. https://doi.org/10.1007/s00203-010-0605-5 PMID: 20661548

7. Osman KM, Elhariri M. Antibiotic resistance of *Clostridium perfringens* isolates from broiler chickens in Egypt. Rev Sci Tech. 2013; 32(3):841–850. PMID: 24761735

8. Gholamiandehkordi A, Eeckhaut V, Lanckriet A, Timberton L, Bjerrum L, Ducatelle R, et al. Antimicrobial resistance in *Clostridium perfringens* isolates from broilers in Belgium. Vet Res Commun. 2009; 33(8):1031–1037. https://doi.org/10.1007/s11259-009-9306-4 PMID: 19597952

9. Adams V, Watts TD, Bulach DM, Lyra D, Rood JL. Plasmid partitioning systems of conjugative plasmids from *Clostridium perfringens*. Plasmid 2015; 80:90–96. https://doi.org/10.1016/j.plasmid.2015.04.004 PMID: 25929175

10. Millet S, Maertens L. The European ban on antibiotic growth promoters in animal feed: from challenges to opportunities. Vet J. 2011; 187(2):143–144. https://doi.org/10.1016/j.tvjl.2010.05.001 PMID: 20627781

11. Caly DL, D’Inca R, Auclair E, Drider D. Alternatives to antibiotics to prevent necrotic enteritis in broiler chickens: a microbiologist’s perspective. Front Microbiol. 2015; 6:1336. https://doi.org/10.3389/fmicb.2015.01336 PMID: 26648920

12. Schneider T, Kruse T, Wimmer R, Wiedemann I, Sass V, Pag U, et al. Plectasin, a fungal defensin, targets the bacterial cell wall precursor Lipid II. Science 2010; 328(5982):1168–1172. https://doi.org/10.1126/science.1185723 PMID: 20508130

13. Zhang J, Yang YL, Teng D, Tian ZG, Wang SR, Wang JH. Expression of plectasin in *Pichia pastoris* and its characterization as a new antimicrobial peptide against *Staphylococcus* and *Streptococcus*. Protein Expr Purif. 2011; 78(2):189–196. https://doi.org/10.1016/j.pep.2011.04.014 PMID: 21558006

14. Zhang Y, Teng D, Mao RY, Wang XM, Xi D, Hu XY, et al. High expression of a plectasin-derived peptide NZ2114 in *Pichia pastoris* and its pharmacodynamics, postantibiotic and synergy against *Staphylococcus aureus*. Appl Microbiol Biotechnol. 2014; 98(2):681–694. https://doi.org/10.1007/s00253-013-4881-2 PMID: 23624708

15. Zhang Y, Teng D, Mao RY, Cao XT, Hu XY, et al. *In vitro* and *in vivo* characterization of a new recombinant antimicrobial peptide, MP1102, against methicillin-resistant *Staphylococcus aureus*. Appl Microbiol Biotechnol. 2015; 99(15):6255–6266. https://doi.org/10.1007/s00253-015-6394-7 PMID: 25620367

16. Cao X, Zhang Y, Mao R, Teng D, Wang X, Wang J. Design and recombination expression of a novel plectasin-derived peptide MP1106 and its properties against *Staphylococcus aureus*. Appl Microbiol Biotechnol. 2015; 99(6):2649–2662. https://doi.org/10.1007/s00253-014-6077-9 PMID: 25261129
18. Mygind PH, Fischer RL, Schnorr KM, Hansen MT, Sönnensen CP, Ludvigsen S, et al. Plectasins are a new class of antibiotics with therapeutic potential from a saprophytic fungus. Nature 2005; 437(7061):975–80. https://doi.org/10.1038/nature04051 PMID: 16222292

19. Hara S, Mukae H, Sakamoto N, Ishimoto H, Amenomori M, Fujita H, et al. Plectasin has antibacterial activity and no effect on cell viability or IL-8 production. Biochem Biophys Res Commun. 2008; 374 (4):709–713. https://doi.org/10.1016/j.bbrc.2008.07.093 PMID: 18675251

20. Andes D, Craig W, Nielsen LA, Kristensen HH. In vivo pharmacodynamics characterization of a novel plectasin antibiotic, NZ2114, in a murine infection model. Antimicrob Agents Chemother. 2009; 53 (7):3003–3009. https://doi.org/10.1128/AAC.01584-08 PMID: 19414576

21. Jiao J, Mao RY, Wang XM, Zhang Y, Teng D, Feng XJ, et al. GAP-initiated constitutive expression of a novel plectasin-derived peptide MP1106 by Pichia pastoris and its activity against Streptococcus suis. Process Biochem. 2015; 50(2):253–261.

22. Xi D, Teng D, Wang XM, Mao RY, Yang YL, Xiang WS, et al. Design, expression and characterization of the hybrid anti microbial peptide LHP7, connected by a flexible linker, against Staphylococcus and Streptococcus. Process Biochem. 2013; 48(3):453–461.

23. Zong LF, Teng D, Wang XM, Mao RY, Yang Y, Hao Y, et al. Mechanism of action of a novel recombinant peptide, MP1102, against Clostridium perfringens type C. Appl Microbiol Biotechnol. 2016; 100 (11):5045–5057. https://doi.org/10.1007/s00253-016-7387-x PMID: 26921181

24. Giguère S, Lee EA, Guldbech KM, Berghaus LJ. In vitro synergy, pharmacodynamics, and postantibiotic effect of 11 antimicrobial agents against Rhodococcus equi. Vet Microbiol. 2012; 160(1–2):207–213. https://doi.org/10.1016/j.vetmic.2012.05.031 PMID: 22704561

25. Teng D, Wang XM, Xi D, Mao RY, Zhang Y, Guan QF, et al. A dual mechanism involved in membrane and nucleic acid disruption of AvBD103b, a new avian defense from the king penguin, against Salmonella enteritidis CVCC3377. Appl Microbiol Biotechnol. 2014; 98(19):8313–8325. https://doi.org/10.1007/s00253-014-5898-x PMID: 24981062

26. Brandenburg LO, Merres J, Albrecht LJ, Varoga D, Pufe T. Antimicrobial peptides: multifunctional drugs for different applications. Polymers 2012; 4(1):539–560.

27. Hall MJ, Middleton RF, Westmacott D. The fractional inhibitory concentration (FIC) index as a measure of synergy. J Antimicrob Chemother. 1982; 11:427–433.

28. Tsuji BT, Rybak MJ. Etest synergy testing of clinical isolates of Staphylococcus aureus demonstrating heterogeneous resistance to vancomycin. Diagn Microbiol Infect Dis. 2006; 54(1):73–77. https://doi.org/10.1016/j.diagmicrobio.2005.08.014 PMID: 16368477

29. Joshi S, Bisht GS, Rawat DS, Kumar A, Kumar R, Maiti S, et al. Interaction studies of novel cell selective antimicrobial peptides with model membranes and E. coli ATCC 11775. Biochim Biophys Acta 2010; 1798(10):1864–1875. https://doi.org/10.1016/j.bbamcr.2010.06.016 PMID: 20599694

30. Aranyi C, Fenters J, Tolkacz V. Examination of virus-infected cultured cells by scanning electron microscopy. Appl Microbiol. 1970; 20(4):633–637. PMID: 5498615

31. Hao Y, Yang N, Wang XM, Teng D, Mao RY, Wang X, et al. Killing of Staphylococcus aureus and Salmonella enteritidis and neutralization of lipopolysaccharide by 17-residue bovine lactoferricins: improved activity of Trp/Ala-containing molecules. Sci Rep. 2017; 7:44278. https://doi.org/10.1038/srep44278 PMID: 28287172

32. Wang XM, Teng D, Mao RY, Yang N, Hao Y, Wang JH. Combined systems approaches reveal a multistage mode of action of a marine antimicrobial peptide against pathogens Escherichia coli and its protective effect against bacterial peritonsillitis and endotoxemia. Antimicrob Agents Chemother. 2017; 61 (1):e01056–16. https://doi.org/10.1128/AAC.01056-16 PMID: 27795369

33. Li L, Shi Y, Cheserek MJ, Su G, Le G. Antibacterial activity and dual mechanisms of peptide analog derived from cell-penetrating peptide against Salmonella typhimurium and Streptococcus pyogenes. Appl Microbiol Biotechnol. 2013; 97(4):1711–1723. https://doi.org/10.1007/s00253-012-4352-1 PMID: 22923068

34. Nagababu P, Shilpa M, Latha JN, Bhatnagar I, Srinivas PN, Kumar YP, et al. Synthesis, characterization, DNA binding properties, fluorescence studies and toxic activity of cobalt (III) and ruthenium (II) polypyrrolidyl complexes. J Fluoresc. 2011; 21(2):563–572. https://doi.org/10.1007/s10895-010-0743-9 PMID: 20931268

35. de Souza Cândido E, e Silva Cardoso MH, Sousa DA, Viana JC, de Oliveira-Júnior NG, Miranda V1, Franco OL. The use of versatile plant antimicrobial peptides in agribusiness and human health. Peptides 2014; 55(5):65–78.

36. Mihajlović M, Lazaridis T. Antimicrobial peptides bind more strongly to membrane pores. Biochim Biophys Acta 2010; 1798(8):1494–1502. https://doi.org/10.1016/j.bbamcr.2010.02.023 PMID: 2018066
37. Dempsey CE, Hawrani A, Howe RA, Walsh TR. Amphipathic antimicrobial peptides—from biophysics to therapeutics. Protein Pept Lett. 2010; 17(11):1334–1344. PMID: 20673228

38. Li W, Tailhades J, O’Brien-Simpson NM, Separovic F, Otvos L Jr, Hossain MA, et al. Proline-rich antimicrobial peptides: potential therapeutics against antibiotic-resistant bacteria. Amino Acids 2014; 46 (10):2287–2294. https://doi.org/10.1007/s00726-014-1820-1 PMID: 25141976

39. Kuwano K, Tanaka N, Shimizu T, Nagatoshi K, Nou S, Sonomoto K. Dual antibacterial mechanisms of nisin Z against Gram-positive and Gram-negative bacteria. Int J Antimicrob Agents 2005; 26(5):396–402. https://doi.org/10.1016/j.ijantimicag.2005.08.010 PMID: 16226432

40. Saravanan R, Mohanram H, Joshi M, Domadia PN, Torres J, Ruedl C, et al. Structure, activity and interactions of the cysteine deleted analog of tachyplesin-1 with lipopolysaccharide micelle: Mechanistic insights into outer-membrane permeabilization and endotoxin neutralization. Biochim Biophys Acta. 2012; 1818(7):1613–1624. https://doi.org/10.1016/j.bbamem.2012.03.015 PMID: 22464970

41. Soge OO, Tivoli LD, Meschke JS, Roberts MC. A conjugative macrolide resistance gene, mef(A), in environmental Clostridium perfringens carrying multiple macrolide and/or tetracycline resistance genes. J Appl Microbiol. 2009; 106(1):34–40. https://doi.org/10.1111/j.1365-2672.2008.03960.x PMID: 19120611

42. Lee TH, Hall KN, Aguilar MI. Antimicrobial peptide structure and mechanism of action: A focus on the role of membrane structure. Curr Top Med Chem. 2016; 16(1):25–39. PMID: 26139112

43. van Dijk A, Veldhuizen EJ, Kaikhove SI, Tjeerdsma-van Bokhoven JL, Romijn RA, Haagsman HP. The beta-defensin gallinacin-6 is expressed in the chicken digestive tract and has antimicrobial activity against food-borne pathogens. Antimicrob Agents Chemother. 2007; 51(3):912–922. https://doi.org/10.1128/AAC.00568-06 PMID: 17194828

44. Lee DG, Kim HN, Park Y, Kim HK, Choi BH, Choi CH, et al. Design of novel analogue peptides with potent antibiotic activity based on the antimicrobial peptide, HP (2–20), derived from N-terminus of Helicobacter pylori ribosomal protein L1. Biochim Biophys Acta 2002; 1598(1–2):185–194. PMID: 12147359

45. Chen Y, Mant CT, Farmer SW, Hancock RE, Vasil ML, Hodges RS. Rational design of alpha-helical antimicrobial peptides with enhanced activities and specificity/therapeutic index. J Biol Chem. 2015; 280(13):12316–12329.

46. Zelezetsky I, Tossi A. Alpha-helical antimicrobial peptides—using a sequence template to guide structure-activity relationship studies. Biochim Biophys Acta 2006; 1758(9):1436–1449. https://doi.org/10.1016/j.bbamem.2006.03.021 PMID: 16678118